Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ProPhase Labs stock

Learn how to easily invest in ProPhase Labs stock.

ProPhase Labs Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 129 staff and has a trailing 12-month revenue of around $131.3 million.

How to buy shares in ProPhase Labs

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

ProPhase Labs stock price (NASDAQ: PRPH)

Use our graph to track the performance of PRPH stocks over time.

ProPhase Labs shares at a glance

Information last updated 2022-09-25.
Latest market close$10.16
52-week range$4.53 - $15.25
50-day moving average $11.31
200-day moving average $8.95
Wall St. target price$11.67
PE ratio 6.8649
Dividend yield $0 (0%)
Earnings per share (TTM) $1.48

Buy ProPhase Labs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ProPhase Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProPhase Labs price performance over time

Historical closes compared with the close of $10.16 from 2022-09-23

1 week (2022-09-19) -6.19%
1 month (2022-08-26) -16.79%
3 months (2022-06-24) -13.38%
6 months (2022-03-22) N/A
1 year (2021-09-24) 100.00%
2 years (2020-09-25) 165.27%
3 years (2019-09-25) 408.00%
5 years (2017-09-26) 372.56%

Is ProPhase Labs stock undervalued or overvalued?

Valuing ProPhase Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ProPhase Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ProPhase Labs's P/E ratio

ProPhase Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, ProPhase Labs shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

ProPhase Labs's EBITDA

ProPhase Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $41.4 million.

The EBITDA is a measure of a ProPhase Labs's overall financial performance and is widely used to measure a its profitability.

ProPhase Labs financials

Revenue TTM $131.3 million
Operating margin TTM 28.01%
Gross profit TTM $42 million
Return on assets TTM 26.37%
Return on equity TTM 45.82%
Profit margin 20.23%
Book value $4.34
Market capitalisation $162.6 million

TTM: trailing 12 months

ProPhase Labs share dividends


Dividend payout ratio: 35.93% of net profits

Recently ProPhase Labs has paid out, on average, around 35.93% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 13.16% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ProPhase Labs shareholders could enjoy a 13.16% return on their shares, in the form of dividend payments. In ProPhase Labs's case, that would currently equate to about $0 per share.

While ProPhase Labs's payout ratio might seem fairly standard, it's worth remembering that ProPhase Labs may be investing much of the rest of its net profits in future growth.

ProPhase Labs's most recent dividend payout was on 2 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 23 May 2022 (the "ex-dividend date").

Have ProPhase Labs's shares ever split?

ProPhase Labs's shares were split on a 2:1 basis on 22 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.

ProPhase Labs share price volatility

Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $4.5346 up to $15.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is -0.4195. This would suggest that ProPhase Labs's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ProPhase Labs has bucked the trend.

ProPhase Labs overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation.

Frequently asked questions

What percentage of ProPhase Labs is owned by insiders or institutions?
Currently 20.169% of ProPhase Labs shares are held by insiders and 13.127% by institutions.
How many people work for ProPhase Labs?
Latest data suggests 129 work at ProPhase Labs.
When does the fiscal year end for ProPhase Labs?
ProPhase Labs's fiscal year ends in December.
Where is ProPhase Labs based?
ProPhase Labs's address is: 711 Stewart Avenue, Garden City, NY, United States, 11530
What is ProPhase Labs's ISIN number?
ProPhase Labs's international securities identification number is: US74345W1080
What is ProPhase Labs's CUSIP number?
ProPhase Labs's Committee on Uniform Securities Identification Procedures number is: 74345W108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site